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1 MPGN 5.4% 2.7% 20.0% C3 2 + (CW) Endotheliocyte injuried，subendothelial
expansion with fluffy material
2 MPGN 55.0% 0.0% 25.0% C3 2 + (CW and MES) electron-dense deposits in MES and SU
3 MPGN 17.6% 0.0% 20.0% C3 2 + (CW and MES) electron-dense deposits in MES
4 MPGN 0.0% 0.0% 25.0% C3 2 + (CW and MES) subendothelial expansion with fluffy material
5 MPGN 14.9% 3.7% 10.0% C3 2 + (CW) electron-dense deposits in MES and SU
6 MPGN 9.1% 0.0% 5.0% C3 2 + (CW and MES) electron-dense deposits in MES, SU and SE
7 MPGN 28.6% 0.0% 4.0%% C3 3 + (CW and MES)/IgG, IgM (trace) electron-dense deposits in MES, SU
MPGN Z membranoproliferative glomerulonephritis; CW Z capillary wall; MES Z mesangial; SE Z subepithelial; SU Z subendothelial.
S62 Other Specific NephropathiesConclusion: Monoclonal gammopathy was a predominant cause of
C3 GN in the older patients. Pattern of pathological injury was membra-
noproliferative. Immunodepressive therapy may be effective,
but the key point of therapy should be targeting monoclonal
gammopathy.http://dx.doi.org/10.1016/j.hkjn.2015.09.0100066
PLA2R Autoantibodies and Glomerular PLA2R Deposit in Membranous
Nephropathy: How to Evaluate the Roles they Played?
H. Z. Qin, W. B. Le, M. C. Zhang, C. H. Zeng, H. Chen, Q. Ren, D. C. Chen,
K. Zuo, F. Xu, Z. H. Liu
National Clinical Research Center of Kidney Diseases, Jinling Hospital,
Nanjing University School of Medicine, Nanjing, Jiangsu, China
Background: Higher glomerular PLA2R-antigen deposit (GAg) rates
compared with serum phospholipase A2 receptor-antibody (SAb) positive
rates were reported. However, the exact roles played by these two bio-
markers remain unknown.
Methods: A total of 572 patients diagnosed with IMN were included. Both SAb
and GAg were detected. Fifty-two IMN patients received repeat renal biopsy
were included.
Results: 572 patients, 401 (70.1%) were SAb positive (SAb+) while 171
(29.9%) were SAb negative (SAb-). In SAb+ patients, the glomerular
PLA2R-antigen deposition (GAg+) was observed in 99.1% (397/401). Inter-
estingly, the GAg+ was observed in 68.4% (117/171) Sab patients. Pa-
tients with SAb manifested more severe proteinuria (3.9 g/24 hours
vs. 2.8 g/24 hours, P < 0.001) and lower eGFR (104 ml/min/1.73 m2
vs. 110 ml/min/1.73 m2, P Z 0.002) than patients without SAb. Further
comparison between SAb+/GAg+ and SAb-/GAg+ showed a similar profile.
Patients with SAb+/GAg+ also showed lower chance of proteinuria
remission and higher chance of renal function decline in the follow up
when compared to patients with SAb-/GAg+. Changes of SAb and
GAg were observed in patients with repeat renal biopsy, in 11 patients
the SAb+ turned into SAb-, among them 1 patient failed to achieve
remission, 7 patients achieved remission and 4 remitted during the in-
terval but relapsed at the time of repeat biopsy. While the GAg+
turned into GAg- in only 3 patients, all achieved remission at the repeat
biopsy. The proportion of GAg disappearance was lower than SAb
(P Z 0.016).
Conclusion: The GAg deposit can be detected in a large proportion of SAb
negative patients, which can be explained by the lag of GAg disappearance
in the follow up. SAb was more tightly correlated to disease activity, treat-
ment response and prognosis than GAg. We recommend adopting GAg depo-
sit detection as a supplement to SAb in IMN diagnosis and continuing to
monitor SAb during follow-up.http://dx.doi.org/10.1016/j.hkjn.2015.09.0110074
sFlt-1 is Regulated via Both Transcriptional and Post-transcriptional
Modification in Preeclampsia
W. Wang1, N. Parchim2, R. Luo1, L. Tao1, Y. Xia2
1Department of Nephrology, Xiangya Hospital, Central South University,
Changsha, Hunan Province, China
2Biochemistry and Molecular Biology Department, University of Texas
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Background: Preeclampsia (PE) is a life-threatening hypertensive disorder of
pregnancy. Soluble fms-like tyrosine kinase 1 (sFlt-1) is elevated and known
to contribute to PE. However, molecular basis underlying its up-regulation in
PE remain unclear.
Methods and Results: By using immunohistochemistry and western blot, we
demonstrated hypoxia inducible factor-1a (HIF-1a), an important transcrip-
tional factor, andU2 small nuclear ribonucleoprotein auxiliary factor 65-kilodal-
ton subunit (U2AF65), a key factor involved in alternative splicing, are
significantly increased in the placental tissue fromPEpatients.Using two animal
models of PE including angiotensin II type 1 receptor agonistic autoantibody
(AT1-AA) and LIGHT (a TNF-a superfamily member)-induced PE mouse model
coupled with in vivo nanoliposome-delivery system to specifically knockdown
HIF-1a and U2AF65, we found that knockdown of HIF-1a or U2AF65 siRNA signif-
icantly attenuated AT1-AA-induced hypertension (HIF-1a siRNA: 137 4mmHg;
U2AF65 siRNA: 140 5 mmHg vs. AT1-AA group 164 3 mmHg, p < 0.05), pro-
teinuria (HIF-1a siRNA: 41.6 3.2 mg/mg, U2AF65 siRNA: 34.9 5.3 mg/mg vs.
AT1-AA group 85.9 4.8 mg albumin/mg creatinine, p < 0.05) and circulating
sFlt-1 level. Similarly, we found thatHIF-1a andU2AF65 knockdown significantly
reduced sFlt-1 levels, hypertension and proteinuria in LIGHT-infused pregnant
mice. Finally, using splice-specific PCR assay, we found that knockdown HIF-
1a significantly reduced total Flt-1 mRNA level in the placentas of both AT1-AA
and LIGHT-infused pregnant mice but no effect on the ratio of sFlt-1/ Flt-1. In
contrast, U2AF65 knock down significantly reduced the ratio of sFlt-1/ Flt-1
without an effect on total Flt-1 mRNA level in these two PE mouse models.
Conclusion: Overall, we have revealed two molecular basis underlying sFlt-1
inductions in PE: (1) elevated HIF-1a directly increases sFlt-1 levels under
transcriptional levels; (2) elevated U2AF65 enhances alternative splicing to
increase sFlt-1 levels.http://dx.doi.org/10.1016/j.hkjn.2015.09.0120078
Long Non-coding RNA_5318 is a Novel Therapeutic Target for Renal
Fibrosis in Obstructive Nephropathy
M. Feng1,2, P. Tang1, Y. K. You1, L. L. Lv1, X. R. Huang1, A. P. Xu2, H. Y. Lan1
1Department of Medicine and Therapeutics, Li Ka Shing Institute of Health
Sciences, CUHK-Shenzhen Research Institute, The Chinese University of
Hong Kong, Hong Kong, China
2Department of Nephrology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen
University, Guangzhou, China
Objective: Long non-coding RNAs (lncRNAs) exert pathophysiologic functions in
many diseases. By using RNA sequencing,we recently found that lncRNA_5318 is
Other Specific Nephropathies S63markedly upregulated in mouse kidney with unilateral ureteral obstruction
(UUO). In this study, we characterized and investigated the regulatory mecha-
nisms and functional role of lncRNA_5318 in renal fibrosis in vitro and in vivo.
Methods: In vitro, the regulatory mechanism of lncRNA_5318 was determined
in TGF-b1-stimuatedmouse tubular epithelial cells (mTECs) with addition of a
Smad3 inhibitor (SIS3). The functional role of lncRNA_5318 in renal fibrosis was
examined in mTECs with knockdown of lncRNA_5318. Furthermore, the func-
tional role and therapeutic potential of lncRNA_5318 for renal fibrosis was
investigated in a mouse UUO model by ultrasound mediated shRNA transfer.
Results: We found that upregulation of lncRNA_5318 in UUO kidney was asso-
ciated with marked activation of TGF-b/Smad3 signaling and progressive
renal fibrosis. In vitro study showed that addition of TGF-b1 induced signif-
icant upregulation of lncRNA_5318 in mTECs by time and dose dependent
manners, which was suppressed by blocking Smad3 signaling with SIS3,
demonstrating a TGF-b/Smad3-dependent regulatory mechanism of
lncRNA_5318 during renal fibrosis. Knockdown of lncRNA_5318 on mTECs
inhibited TGF-b1- induced expression of collagen I and a-SMA which revealed
the functional role of lncRNA_5318 in TGF-b-induced fibrosis. Furthermore,
we also demonstrated that gene therapy of mouse UUO by shRNA was
capable of blocking lncRNA_5318, thereby inhibiting renal fibrosis.
Conclusion: lncRNA_5318 is positively regulated by TGF-b/Smad3 signaling
and functions to medicate renal fibrosis. Inhibition of progressive renal
fibrosis by blocking lncRNA_5318 with shRNA demonstrates a novel therapy
for renal fibrosis by targeting lncRNA_5318.http://dx.doi.org/10.1016/j.hkjn.2015.09.0130081
A Cost-effective Genetic Diagnosis of Autosomal Dominant Polycystic
Kidney Disease and Correlation with Phenotype
Daw-Yang Hwang, Chi-Chih Hung, Hung-Chun Chen
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the
most common monogenic kidney disease. Genetic testing of ADPKD is expen-
sive because of 6 pseudogenes and 33 exons in PKD1. Previous methods
included (1) long range PCR followed by direct sequencing, (2) whole-exome
sequencing with custom-made target capture array, and (3) long-range PCR
amplicons and barcoded libraries followed by next generation sequencing.
We propose a cost effective method by target sequencing of combining
multiplex PCR amplicons followed by next generation sequencing.
Methods: We studied 51 PKD patients diagnosed as ADPKD with typical
numerous renal cysts with or without family history.We compared ourmethod
with traditional method and validated by a traditional method in 20 cases.
Results: Themutation detection rate is 80% in the cohort. PKD2mutations per-
centage are higher in the Taiwan ADPKD population (35.3%) compared to pre-
vious report (15%). Several novelmutations are found in PKD1 and PKD2. There
was no hot spot in PKD1. A hot spot R803X of PKD2 was found in 15% of the
cohort, and a funder effect was suspected. The renal survival was better in
those with PKD2 mutation. The renal survival in PKD2 patients with mutation
after the intracellular coil-coil domain was not better than those with muta-
tion before this area. The cost of this method is below US$300 per person.
Conclusion: Our method generates a reasonable detection rate with lower
price. Individual treatment based on genetic diagnosis could a future of
ADPKD treatment.http://dx.doi.org/10.1016/j.hkjn.2015.09.0140082
A Discrepancy of Parallel Correlation Between Proteinuria and Levels of
Anti-phospholipase A2 Receptor Antibody in Patients with Idiopathic
Membranous Nephropathy
Yu-Jen Su, Wen-Chin Lee, Ben-Chung Cheng, Lung-Chih Li, Jin-Bor Chen
Division of Nephrology, Kaohsiung Chang Gung Memorial Hospital,
Kaohsiung, Taiwan
Objectives: To assess the prevalence of anti-phospholipase A2 receptor
(anti-PLA2R) antibody in a cohort of patients with idiopathic membranousnephropathy (MN) in Taiwan and to correlate the presence of anti-PLA2R
antibody with the clinical parameters reflective of disease activity. In
addition, to monitor disease activity using levels of anti-PLA2R antibody
in MN.
Methods: The preliminary report was a cross-sectional in prevalent patients
with MN, which prospective collection of serum and urine checked together
with clinical data. MN definitively pathological diagnosis, not only new inci-
dent (treatment naı¨ve) patients, but also active patients entering therapeu-
tic trial (including immunosuppressive agents) and adult patients > 18 years
old are enrolled. We quantified anti-PLA2R antibody by ELISA (EUROIMMUN
AG) that provides reliable determination and also quantification of autoan-
tibodies (IgG) against PLA2R.
Results: So far, the number of MN cases collected is 17. Control group,
including other glomerculonephritis or health people is 13. In four of those
17 MN patients, anti-PLA2R antibodies were positive (detectable > 20 RU/
ml, ELISA). None of control group was positive anti-PLA2R antibodies. The
prevalence of anti-PLA2R antibodies was relatively low compared to China
cohort, because our cohort was cross-sectional study. Serum samples
collected from MN patients were almost those accepted steroid or other
immunosuppressant agents. Anti-PLA2R antibodies might be underesti-
mated. Changes in serum anti-PLA2R antibodies levels as dynamic clinical
parameters for disease activity are enrolling. So far, it showed no this asso-
ciation. However, we observe anti-PLA2R antibody levels may correlate with
urinary excretion of b2 microglobulin or IgG, a marker of renal damage
rather than proteinuria.
Conclusion: The preliminary report did not demonstrate the association be-
tween the disease activities with anti-PLA2R antibodies in idiopathic MN
from the experience in Southern Taiwan.http://dx.doi.org/10.1016/j.hkjn.2015.09.0150108
Primary and Recurrent Focal Segmental Glomerulosclerosis Closely
Linked to Serum Soluble Urokinase-type Plasminogen Activator
Receptor Levels
Juan Jin, Yi Wen Li, Qiang He
Zhejiang Province People’s Hospital, Hangzhou, Zhejiang, China
Background: Serum soluble urokinase-type plasminogen activator receptor
(suPAR) is implicated in the pathogenesis of native and recurrent FSGS. It
is elevated in two-thirds of subjects with primary FSGS, but not in people
with other glomerular diseases which can differentiate FSGS and other
glomerular diseases.
Methods: We measured soluble urokinase receptor levels in the resum
of patients with primary focal segmental glomerulosclerosis (FSGS)
and determined their association with clinical and pathological data in
86 patients with primary FSGS, 5 repeat renal biopsy FSGS and 6
recurrent FSGS posttranplantation, healthy controls and patients
with minimal change disease, and membranous nephropathy were
used as controls. The suPAR levels were measured by commercial ELISA
kits.
Results: Of patients with primary FSGS (median 4232, interquartile range
1299e9714 pg/ml) were significantly higher than those of patients with min-
imal change disease (median 2784 pg/ml), membranous nephropathy (me-
dian 3478 pg/ml), and healthy individuals (median 1994 pg/ml). There was
no significant difference in suPAR levels between the 65 patients with min-
imal change disease and 85 patients with membranous nephropathy. The
suPAR levels increased in the 5 repeated renal biopsy FSGS and 6 recurrent
FSGS posttranplantation.
Conclusion: The suPAR levels were significantly but positively correlated
with FSGS, not only primary FSGS but also recurrent FSGS posttransplanta-
tion, but negatively correlated with other glomerular diseases. Thus,
suPAR levels can differentiate primary FSGS and other glomerular
diseases.http://dx.doi.org/10.1016/j.hkjn.2015.09.016
